Proteros Biostructures GmbH has announced that it has renewed its agreement with Rigel Pharmaceuticals, Inc. to provide structural biology services for a Rigel drug discovery program.
Under this agreement, Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts.
Proteros will deploy its high throughput crystallography platform and proprietary technologies.
Proteros focuses on providing structure based drug discovery services and continues to invest in developing its service platform which consists of X-ray protein crystallography, kinetic and thermodynamic compound profiling and integrated lead discovery based on a novel compound and fragment library of over 30,000 novel target directed molecules.
Cony D’Cruz, CBO and President of Proteros (US) Inc. said: “This agreement continues long-standing structural biology collaboration between the two companies. We are pleased to be supporting Rigel with its pioneering research efforts.”